TrialCNS drugs2018

Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson's Disease.

Lawrence W Elmer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.